Head-to-Head: which drug tames high prolactin better?
NCT ID NCT07124221
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether cabergoline works better than bromocriptine for women with high prolactin levels. About 382 women aged 18-45 will take one of the two drugs for 14 weeks. The main goal is to see whose prolactin levels return to normal, along with checking ovulation, breast discharge, and tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cabergoline tablets
- What this could lead to
- If cabergoline works better or has fewer side effects than bromocriptine, it could become a preferred treatment for women with high prolactin levels.
- What could go wrong
- This is a Phase 3 trial, but both drugs are already approved; the main question is which is better. Some women may not respond or may experience side effects like nausea or dizziness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERPROLACTINEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.